<p>Bioventus Inc.（紐約證券交易所代碼：BVS - 獲取免費報告）董事 Guy Nohra 於 12 月 4 日星期四出售了 10,000 股公司的股票。股票以平均價格 7.57 美元出售，總交易額為 75,700.00 美元。出售後，該董事持有 116,610 股公司的股票，價值約為 882,737.70 美元。這代表其持股比例減少了 7.90%。該交易已在向 SEC 提交的法律文件中披露，文件可通過此鏈接獲取。</p>
<h2>Bioventus 股票表現</h2>
<p>BVS 的股票在週一交易時段上漲 0.10 美元，達到 7.19 美元。該股票的交易量為 277,376 股，而其平均交易量為 374,594 股。Bioventus Inc.的 12 個月最低價為 5.81 美元，最高價為 11.85 美元。該公司的市值為 5.9507 億美元，市盈率為-11.79，貝塔值為 0.79。公司的債務與股本比率為 1.85，流動比率為 1.41，速動比率為 0.99。該股票的 50 日移動平均價格為 7.08 美元，200 日移動平均價格為 6.93 美元。</p>
<h2>對 Bioventus 的對沖基金看法</h2>
<p>機構投資者最近買入和賣出了該股票的股份。Russell Investments Group Ltd.在第一季度將其在 Bioventus 的股份提高了 23,761.5%。Russell Investments Group Ltd.現在擁有 6,204 股公司的股票，價值 57,000 美元，此前在上個季度又購買了 6,178 股。Covestor Ltd 在第三季度將其在 Bioventus 的股份提高了 28.0%。Covestor Ltd 現在擁有 9,951 股公司的股票，價值 67,000 美元，此前在上個季度又購買了 2,176 股。PharVision Advisers LLC 在第二季度購買了 Bioventus 的新股份，價值 67,000 美元。HB Wealth Management LLC 在第三季度購買了 Bioventus 的新職位，價值約 72,000 美元。最後，Fox Run Management L.L.C.在第二季度獲得了 Bioventus 的新職位，價值 72,000 美元。62.94% 的股票由機構投資者持有。</p>
<h2>Bioventus 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Bioventus Inc 是一家醫療設備公司，專注於開發和商業化治療方法，以促進和增強身體的自然癒合過程，業務遍及美國及國際市場。公司的產品組合包括疼痛治療，涵蓋非手術疼痛注射療法，以及外周神經刺激產品，如 Durolane、GELSYN-3 和 SUPARTZ，用於治療膝關節骨關節炎，以及 Stimrouter 用於治療慢性外周疼痛。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 Bioventus 更好</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次上漲</li>
<li>投資組合提升的三隻最佳金融科技股票</li>
<li>內部人士正在出售的五隻科技股票（但聰明的投資者正在加倉）</li>
<li>什麼是微型股？您需要知道的一切</li>
<li>為什麼 FuelCell Energy 的股票在政府交易後飆升</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJWUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>您現在應該投資 1,000 美元在 Bioventus 嗎？</h2>
<p>在您考慮 Bioventus 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bioventus 並不在名單上。</p>
<p>雖然 Bioventus 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Bioventus Inc. 董事 Guy Nohra 出售了 10,000 股，交易金額為 75,700 美元，減少了 7.90% 的持股比例。出售後，他持有 116,610 股，價值 882,737.70 美元。該交易已在 SEC 文件中披露。Bioventus 股票交易價格為 7.19 美元，市值為 5.9507 億美元。機構投資者持有 62.94% 的股份。Bioventus 開發用於疼痛治療的醫療設備</p>

<p>Bioventus Inc. (NYSE:BVS - Get Free Report) Director Guy Nohra sold 10,000 shares of the business's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $7.57, for a total transaction of $75,700.00. Following the sale, the director owned 116,610 shares of the company's stock, valued at approximately $882,737.70. This represents a 7.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.</p>
<div class="lb-trans"><p>Bioventus Inc.（紐約證券交易所代碼：BVS - 獲取免費報告）董事 Guy Nohra 於 12 月 4 日星期四出售了 10,000 股公司的股票。股票以平均價格 7.57 美元出售，總交易額為 75,700.00 美元。出售後，該董事持有 116,610 股公司的股票，價值約為 882,737.70 美元。這代表其持股比例減少了 7.90%。該交易已在向 SEC 提交的法律文件中披露，文件可通過此鏈接獲取。</p>
</div><h2>Bioventus Stock Performance</h2>
<div class="lb-trans"><h2>Bioventus 股票表現</h2>
</div><p>Shares of BVS traded up $0.10 during trading hours on Monday, hitting $7.19. The stock had a trading volume of 277,376 shares, compared to its average volume of 374,594. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $11.85. The firm has a market capitalization of $595.07 million, a PE ratio of -11.79 and a beta of 0.79. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock has a fifty day moving average price of $7.08 and a 200 day moving average price of $6.93.</p>
<div class="lb-trans"><p>BVS 的股票在週一交易時段上漲 0.10 美元，達到 7.19 美元。該股票的交易量為 277,376 股，而其平均交易量為 374,594 股。Bioventus Inc.的 12 個月最低價為 5.81 美元，最高價為 11.85 美元。該公司的市值為 5.9507 億美元，市盈率為-11.79，貝塔值為 0.79。公司的債務與股本比率為 1.85，流動比率為 1.41，速動比率為 0.99。該股票的 50 日移動平均價格為 7.08 美元，200 日移動平均價格為 6.93 美元。</p>
</div><h2>Hedge Funds Weigh In On Bioventus</h2>
<div class="lb-trans"><h2>對 Bioventus 的對沖基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its stake in shares of Bioventus by 23,761.5% during the 1st quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company's stock worth $57,000 after acquiring an additional 6,178 shares during the last quarter. Covestor Ltd lifted its stake in shares of Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company's stock worth $67,000 after purchasing an additional 2,176 shares during the last quarter. PharVision Advisers LLC purchased a new stake in shares of Bioventus during the 2nd quarter valued at $67,000. HB Wealth Management LLC purchased a new position in shares of Bioventus in the 3rd quarter valued at approximately $72,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Bioventus in the 2nd quarter valued at $72,000. 62.94% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該股票的股份。Russell Investments Group Ltd.在第一季度將其在 Bioventus 的股份提高了 23,761.5%。Russell Investments Group Ltd.現在擁有 6,204 股公司的股票，價值 57,000 美元，此前在上個季度又購買了 6,178 股。Covestor Ltd 在第三季度將其在 Bioventus 的股份提高了 28.0%。Covestor Ltd 現在擁有 9,951 股公司的股票，價值 67,000 美元，此前在上個季度又購買了 2,176 股。PharVision Advisers LLC 在第二季度購買了 Bioventus 的新股份，價值 67,000 美元。HB Wealth Management LLC 在第三季度購買了 Bioventus 的新職位，價值約 72,000 美元。最後，Fox Run Management L.L.C.在第二季度獲得了 Bioventus 的新職位，價值 72,000 美元。62.94% 的股票由機構投資者持有。</p>
</div><h2>Bioventus Company Profile</h2>
<div class="lb-trans"><h2>Bioventus 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.</p>
<div class="lb-trans"><p>Bioventus Inc 是一家醫療設備公司，專注於開發和商業化治療方法，以促進和增強身體的自然癒合過程，業務遍及美國及國際市場。公司的產品組合包括疼痛治療，涵蓋非手術疼痛注射療法，以及外周神經刺激產品，如 Durolane、GELSYN-3 和 SUPARTZ，用於治療膝關節骨關節炎，以及 Stimrouter 用於治療慢性外周疼痛。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Bioventus</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up)</li>
<li>What is a Microcap Stock? Everything You Need to Know</li>
<li>Why FuelCell Energy Stock Is Soaring After a Government Deal</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Bioventus 更好</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次上漲</li>
<li>投資組合提升的三隻最佳金融科技股票</li>
<li>內部人士正在出售的五隻科技股票（但聰明的投資者正在加倉）</li>
<li>什麼是微型股？您需要知道的一切</li>
<li>為什麼 FuelCell Energy 的股票在政府交易後飆升</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJWUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=BVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bioventus Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Bioventus 嗎？</h2>
</div><p>Before you consider Bioventus, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Bioventus 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bioventus 並不在名單上。</p>
</div><p>While Bioventus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bioventus 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bioventus (NYSE:BVS) 的一位董事出售了價值 75,700.00 美元的股票